[Alpha Biz=(Chicago) Reporter Kim Jisun] Samsung BioLogics said on the 6th that it has expanded its contract for drug consignment production (CMO) with Eli Lilly Kinsale Limited, the Irish production company of Eli Lilly, a global pharmaceutical company, to KRW 327.8 billion.
This amounts to 28.14% of Samsung Biologics' consolidated sales in 2020. The contract was first signed in December 2019 and will end in December 2029.
With this contract, Samsung Biologics and Eli Lilly Kinsale increased the contract amount by 215.6 billion won. The two companies also increased their contracts to 112.1 billion won in March 2022.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
